We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

21 hedge funds and large institutions have $2.6M invested in Benitec Biopharma in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

24% more funds holding

Funds holding: 17 → 21 (+4)

0.12% less ownership

Funds ownership: 19.47% → 19.36% (-0.12%)

9% less capital inflows, than outflows

Capital inflows: $243K | Capital outflows: $267K

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
21
Holders Change
+4
Holders Change %
+23.53%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$143K
2
Atom Investors
Atom Investors
Texas
+$91K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$3.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.82K
5
State Street
State Street
Massachusetts
+$1.08K

Top Sellers

Rank Fund Capital Flow
1
Silverarc Capital Management
Silverarc Capital Management
Massachusetts
-$231K
2
Virtu Financial
Virtu Financial
New York
-$27K
3
UBS Group
UBS Group
Switzerland
-$6.76K
4
BlackRock
BlackRock
New York
-$2.32K

BNTC Hedge Fund Activity: Q1 2022 in Review

21 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2022, worth a combined $2.6M — down 38% from $4.16M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BNTC positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Barclays, opening a new position worth an estimated $143K. The largest seller was Silverarc Capital Management, cutting an estimated $231K.

  • 21 institutional investors held Benitec Biopharma (BNTC) as of Q1 2022, up from 17 in Q4 2021.
  • Funds reported $2.6M of Benitec Biopharma stock for Q1 2022, down 38% quarter-over-quarter.
  • 6 funds opened new Benitec Biopharma positions in Q1 2022 and 2 closed out, a net change of +4 holders.
  • The largest Benitec Biopharma buyer in Q1 2022 was Barclays, an estimated $143K added.
  • The largest Benitec Biopharma seller in Q1 2022 was Silverarc Capital Management, an estimated $231K sold.

Based on aggregated 13F filings for Q1 2022.